ibutamoren · MK-0677
A pill that raises growth hormone. It is not a peptide. No such medicine exists.
This site is for information and education only. It does not promote or encourage the use or purchase of the substances described and is not medical advice. Many are not authorised as medicines and their safety has not been established. We sell nothing and have no ties to sellers. For health decisions, consult a doctor.
Safety. A study after hip fracture was stopped early because of possible heart failure. Another study found worse blood sugar control. Sources: study 1, study 2.
Risk of fakes. It turned up among unapproved substances in products sold as SARMs. Only 41% of those products matched the label. Sources: study 1.
| Where | Status | Checked | |
|---|---|---|---|
| PL | No approval | The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. Source | Not yet |
| EU | No approval | The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). Source | Not yet |
| US | No approval | The FDA drug register has no such medicine. Source | Not yet |
Scientific papers per year 2015–2025
These are search results. A count shows how much exists, not how good the studies are. 1 Nov 2026.
Effect in studies. Body mass without fat rose in healthy older adults and obese men, and in a short study the body held on to more protein. No study tested people who train.
No effect in studies. More body mass without fat did not bring more strength or better function in older adults. A study after hip fracture was stopped early for safety reasons.
What doctors, patients and companies reported to the US medicines agency (FDA), and single cases described in medical journals. A report says what happened to someone after taking the substance. It does not prove the substance caused it, and it does not say how often it happens. Reports do not change any grade.
| Most often reported | Reports |
|---|---|
| Stroke | 3 |
| Red blood cells destroyed in the cold | 2 |
| Blood clots more slowly (raised INR) | 2 |
| Yellow skin or eyes | 2 |
| Liver damage | 2 |
| Seizure | 2 |
| Pain in the upper belly | 1 |
| Unusual behaviour | 1 |
Serious means the person went to hospital, their life was in danger, they were left with lasting harm, or they died. One report can list several side effects.
FDA reports come from openFDA, cases from a PubMed search. The editors have not read these cases yet. Titles stay in the original language. As of 3 Nov 2026.
A urologist who works on men's health goes through the studies on popular SARMs, MK-677 and cardarine: muscle gain, lower testosterone, the liver, cholesterol, fertility and false labels. According to the description, every SARM gets the lowest rating at the end.
A urologist who works on men's health covers MK-677 in a short video: strong hunger, water retention, higher blood sugar and a weaker response to insulin. He points out it is still being studied, has no FDA approval, and black-market products may be contaminated.
A doctor who treats men with testosterone compares sermorelin and MK-677, which raise growth hormone in different ways. He talks about side effects he has seen in patients and his concerns about long-term use, including cancer risk with high IGF-1. The video is from 2019.
| Studies | Kind of study | Who was studied | People | Duration | Dose as studied | Who paid |
|---|---|---|---|---|---|---|
| MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. | Random groups | Elderly patients recovering from hip fracture | 123 | 24 wk | 25 mg daily | Unknown |
| Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. | Random groups | Healthy older adults | 65 | 52 wk | 25 mg daily | Unknown |
| MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. | Random groups | Healthy volunteers on a calorie-restricted diet | 8 | 1 wk | 25 mg daily | Unknown |
| Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. | Random groups | Healthy obese men | 24 | 8 wk | 25 mg daily | Unknown |
We found these papers automatically in PubMed. The editors have not read them yet, and they do not affect any grade. Titles stay in the original language.
